GlassScriptPhysician profile
Steven S Maggid
NPI 1821079328
$4,633.50
in general payments reported to CMS, 2019-2025
36 companies · $539 in 2025
The $539 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $149 · 2021: $1,161 · 2022: $1,033 · 2023: $663 · 2024: $583 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,784.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $504.89 | 2021-2023 | |
| Astellas Pharma US INC | $495.03 | 2021-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $463.42 | 2021-2025 | |
| Pfizer INC. | $398.25 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $333.07 | 2023-2025 | Myfembree, Gemtesa |
| Aspira Women'S Health INC | $285.27 | 2021-2022 | |
| Exeltis, USA INC. | $188.15 | 2019-2024 | Slynd |
| Daiichi Sankyo INC. | $187.46 | 2020-2023 | Injectafer |
| Myovant Sciences INC. | $160.97 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $145.28 | 2019-2025 | Gardasil 9, Gardasil |
| Renovia INC | $143.21 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.23 | 2019-2023 | |
| Coopersurgical, INC. | $124.35 | 2019-2024 | Endosee, Advincula Delineator Uterine Manipulator, Mara Console |
| Zyla Life Sciences, INC. | $116.86 | 2019 | |
| Organon LLC | $98.14 | 2021-2025 | Nexplanon |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $95.24 | 2019-2022 | |
| Amgen INC. | $94.35 | 2019-2024 | Prolia, Evenity |
| Avion Pharmaceuticals | $93.07 | 2020-2022 | |
| Millicent US INC | $83.88 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Allergan, INC. | $67.82 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $59.59 | 2019 | |
| Hologic Sales and Service, LLC | $57.48 | 2021-2025 | Aptima, Novasure, Myosure Tissue Removal Device |
| Evofem Biosciences, INC. | $40.46 | 2021-2022 | |
| Lupin INC. | $34.40 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $33.24 | 2021-2022 | |
| Mission Pharmacal Company | $31.69 | 2019 | |
| Vertical Pharmaceuticals, LLC | $26.73 | 2019 | |
| Becton, Dickinson and Company | $24.71 | 2024 | Bd Max System, Bd Max Instrument |
| Myriad Women'S Health, INC. | $18.96 | 2023 | Myrisk |
| Ferring Pharmaceuticals INC. | $17.20 | 2020 | |
| Agile Therapeutics, INC. | $17.04 | 2021 | |
| Roche Diagnostics Corporation | $16.82 | 2019 | |
| Scynexis, INC. | $16.29 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $15.03 | 2023 | Vivjoa |
| Dysis Medical, INC. | $12.92 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Maggid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.